Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany
Objectives Despite national recommendations for use ofpneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasivepneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugatevaccines (PCVs) with expanded coverage have the potential to reduce thepneumococcal diseas...
Saved in:
Main Authors: | Felicitas Kühne (Author), Katharina Achtert (Author), Franziska Püschner (Author), Dominika Urbanski-Rini (Author), Juliane Schiller (Author), Ernestine Mahar (Author), Josephine Friedrich (Author), Mark Atwood (Author), Ralf Sprenger (Author), Jeffrey Vietri (Author), Christof von Eiff (Author), Christian Theilacker (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023) -
Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults
by: Sophie Marbaix, et al.
Published: (2023) -
Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020) -
13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012) -
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)